Bio
Kavita Iyer graduated with a Bachelor of Pharmacy from the University of Mumbai. Subsequently she earned her PhD in Medicinal Chemistry from Virginia Commonwealth University, VCU. She further pursued a post-doctoral fellowship in the Department of Physiology and Biophysics at VCU where she was trained as a structural biologist and subsequently worked as a Research Scientist. While at CAS, Kavita has worked on a wide range of topics including immuno-oncology, CRISPR therapeutics, rare diseases, and nano biosensors in Life Sciences as well as covalent inhibitors and PROTACs in Medicinal Chemistry.
Biotechnology
¿Podría el xenotrasplante resolver la escasez de órganos para trasplantes?
Con la llegada de la tecnología de edición genética, los investigadores son cada vez más capaces de abordar los problemas de inmunocompatibilidad, acercándose a la posibilidad de disponer de órganos y tejidos para trasplantes de donantes animales a receptores humanos.
Drug Discovery
Los inhibidores de PPI para combatir el cáncer están avanzando en ensayos clínicos
Los inhibidores de IPP de moléculas pequeñas están a punto de mejorar los tratamientos contra el cáncer
Ciencia emergente
Los conceptos coocurrentes revelan nuevas direcciones de investigación en inmunooncología
El análisis de la coocurrencia de conceptos muestra las ideas más novedosas en el ámbito de los descubrimientos científicos e impulsa la innovación en inmunooncología.
Drug Discovery
PROTACs revolutionize small molecule drugs
PROTACs are driving small molecule drug development to treat cancer, neurodegenerative diseases and more
Biotechnology
Webinar: Big data insights in the quest to cure cancer
Experts discuss emerging trends in immuno-oncology, data challenges, and opportunities ahead for cancer researchers.
Drug Discovery
Emerging trends in immunotherapy and cancer
Immuno-oncology has the potential to treat cancer without sacrificing the patient's wellbeing.